查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654402

格林-巴利综合症市场规模、份额、趋势分析报告：按治疗方法、类型、给药途径、分销管道、地区、细分预测，2025-2030 年

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

格林-巴利症候群市场成长与趋势

根据 Grand View Research, Inc. 的最新报告，全球格林巴利症候群市场规模预计到 2030 年将达到 10.3 亿美元，预测期内的复合年增长率为 6.10%。

格林-巴利综合症是一种罕见但严重的自体免疫疾病，会影响週边神经系统，其发病率不断上升，为医疗保健领域带来了成长机会。公司可以透过治疗、诊断工具和患者照护解决方案的进步来利用这一市场扩张。人们对静脉注射免疫球蛋白 (IVIG) 和血浆置换等有效治疗方法的需求日益增加，并且需要透过医院和零售药局改善获得这些治疗方法的机会。

GBS 有多种亚型，每种亚型都需要专门的医疗方法。急性发炎性去髓鞘化多发性神经病变 (AIDP) 是北美和欧洲最常见的形式，其特征是进行性肌肉无力和感觉丧失。慢性脱髓鞘多发性神经炎(CIDP) 虽然是一种相关疾病，但它是一种慢性疾病，需要长期管理策略，因此对治疗性介入的需求持续存在。米勒费雪症候群 (MFS) 是一种较为罕见的疾病，主要影响眼球运动和协调能力，需要有针对性的神经系统治疗。急性运动轴突神经病变(AMAN) 在亚洲和拉丁美洲更为常见，凸显了针对特定地区的诊断和治疗发展的必要性。

最近爆​​发的格林巴利症候群（GBS）可能与兹卡和其他新兴病原体等病毒感染有关，引起了市场越来越多的兴趣。病例数量的快速增加促使需要加强监测、早期诊断和及时治疗性介入，并鼓励对医疗基础设施的投资。政府和製药公司正在加紧研发，开发新的治疗方法并改善现有的通讯协定。新冠肺炎疫情导致静脉注射免疫球蛋白和血浆置换（治疗格林-巴利综合症的主要治疗方法）需求旺盛，这给全球血浆供应链带来了压力，并促使替代疗法的创新。

COVID-19 大流行进一步影响了 GBS 市场，因为研究表明 SARS-CoV-2 感染与 GBS 风险增加之间存在关联。 COVID-19 病例激增导致报告的格林-巴利综合症诊断数量增加，并促使对 IVIG 和血浆置换治疗的需求增加。此外，疫情导致的医疗供应链中断影响了人们获得基本治疗的机会，并迫使人们在药品生产和分销方面做出策略性调整。对病毒感染后神经系统併发症的认识和研究不断提高，也推动了对格林-巴利症候群诊断和治疗创新的投资。

治疗方法正在不断发展，目前正在探索非肠道和口服治疗方法。儘管 IVIG 仍然是急性治疗的主要方法，但口服免疫调节疗法的研究日益增多，这可能为 CIDP 患者提供更容易获得的长期治疗方法。药房在格林-巴利综合症治疗药物的分发中发挥关键作用。医院药房占据市场主导地位，因为 IVIG 或血浆置换疗法期间需要住院护理和密切监测。然而，零售药局正在扩大其在 CIDP 管理中的作用，为患者提供方便的维持和支持药物。

由于人们认识的提高、治疗方法的不断发展以及药品投资的增加，GBS 市场预计将大幅成长。急性和慢性护理解决方案的创新将继续塑造格局，为医疗保健和治疗业务创造新的机会。

格林-巴利症候群市场报告重点

  • 2024 年格林巴利症候群治疗市场以静脉注射免疫球蛋白 (IVIG) 为主。这一优势源于 IVIG 已被证明具有调节免疫反应、减缓疾病进展和提高康復率的能力，使其成为 GBS 的首选一线治疗方法。
  • 2024 年，急性发炎性去髓鞘化多发性神经病变 (AIDP) 在 GBS 亚型中占据最大的市场占有率。作为格林巴利症候群最常见的形式，尤其是在北美和欧洲，AIDP疫情正在严重影响对有效治疗方案的需求，进一步加强了市场主导地位。
  • 2024 年，肠外药物将引领 GBS 治疗市场。鑑于疾病的严重性，静脉注射免疫球蛋白（IVIG）和血浆置换等静脉注射治疗可确保快速有效的治疗反应，改善急性和重症患者的预后。
  • 2024年，医院药局仍将是主要的分销管道。由于需要即时进行医疗干预和专门护理，医院药房在确保格林-巴利综合症治疗的可用性和管理方面发挥关键作用，尤其是在急性护理环境中。
  • 由于医疗保健基础设施发达、对神经系统疾病的高度认识以及先进的治疗选择，北美在 GBS 治疗市场处于领先地位。该地区对研究和创新的高度重视进一步推动了市场成长。

目录

第一章调查方法与范围

第 2 章执行摘要

3. 格林-巴利症候群市场变数、趋势与范围

  • 母市场展望
  • 补贴市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 格林-巴利症候群分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章 格林-巴利综合症市场：治疗方法估计和趋势分析

  • 格林-巴利综合症市场：治疗方法细分仪表板
  • 格林-巴利综合症市场：2024 年和 2030 年治疗方法变异分析
  • 静脉注射免疫球蛋白（IVIG）
  • 血浆置换
  • 其他的

第 5 章 格林-巴利综合症市场：按类型估计和趋势分析

  • 格林-巴利综合症市场：类型细分仪表板
  • 格林-巴利症候群市场：类型变异分析，2024 年与 2030 年
  • 急性发炎性去髓鞘化多发性神经病变 (AIDP)
  • 慢性发炎性去髓鞘化多发性神经根神经病变 (CIDP)
  • 米勒费雪症候群（MFS）
  • 急性运动轴索神经病变 (AMAN)
  • 其他的

第 6 章 格林-巴利综合症市场：按给药途径进行的估计和趋势分析

  • 格林-巴利症候群市场：给药途径细分仪表板
  • 格林-巴利综合症市场：2024 年和 2030 年按给药途径进行的变化分析
  • 肠外
  • 口服

第 7 章 格林-巴利综合症市场：按分销管道进行的估计和趋势分析

  • 格林-巴利综合症市场：分销通路细分仪表板
  • 格林-巴利综合症市场：2024 年和 2030 年分销管道变化分析
  • 医院药房
  • 零售药局
  • 其他药局

第 8 章 格林-巴利综合症市场：按地区分類的估计和趋势分析

  • 格林-巴利综合症市场占有率（按地区划分），2024 年和 2030 年，百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 南非

第九章 竞争格局

  • 主要市场参与企业的近期趋势及影响分析
  • 公司分类
  • 2024 年公司市场占有率分析
  • 2024 年企业热图分析
  • 公司简介
    • AbbVie Inc.
    • Biogen
    • Cadila Pharmaceuticals
    • CSL
    • F. Hoffmann-La Roche Ltd.
    • GSK plc.
    • Grifols SA
    • LGM Pharma.
    • Merck &Co., Inc.
    • Octapharma AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: GVR-4-68040-200-8

Guillain-Barre Syndrome Market Growth & Trends:

The global guillain-Barre syndrome market size is anticipated to reach USD 1.03 billion by 2030 and is expected to expand at a CAGR of 6.10% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of Guillain-Barre Syndrome (GBS), a rare but serious autoimmune disorder affecting the peripheral nervous system, is driving growth opportunities in the healthcare sector. Businesses can capitalize on this market expansion through advancements in treatment modalities, diagnostic tools, and patient care solutions. The demand for effective therapies such as Intravenous Immunoglobulin (IVIG) and Plasma Exchange is rising, necessitating improved access to these treatments via hospital and retail pharmacies.

GBS presents in multiple variants, each requiring specialized medical approaches. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) is the most common form in North America and Europe, characterized by progressive muscle weakness and sensory disturbances. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a related but chronic condition, necessitates long-term management strategies, creating sustained demand for therapeutic interventions. Miller Fisher Syndrome (MFS), a rarer variant, primarily affects eye movement and coordination, necessitating targeted neurological treatments. Acute Motor Axonal Neuropathy (AMAN), more prevalent in Asia and Latin America, underscores the need for region-specific diagnostic and therapeutic developments.

Recent outbreaks of GBS, potentially linked to viral infections such as Zika and other emerging pathogens, have intensified market interest. A surge in cases drives the need for enhanced surveillance, early diagnosis, and timely therapeutic intervention, boosting investment in healthcare infrastructure. Governments and pharmaceutical companies are increasing research efforts to develop new treatment options and improve existing protocols. The outbreak-driven demand for IVIG and Plasma Exchange, primary treatments for GBS, has put pressure on global plasma supply chains, encouraging innovation in alternative therapies.

The COVID-19 pandemic has further impacted the GBS market, as studies have indicated a potential association between SARS-CoV-2 infection and an increased risk of GBS. The surge in COVID-19 cases led to a rise in reported GBS diagnoses, driving higher demand for IVIG and Plasma Exchange treatments. In addition, pandemic-related disruptions in healthcare supply chains have affected the availability of essential therapies, necessitating strategic adjustments in pharmaceutical production and distribution. Increased awareness and research into post-viral neurological complications have also propelled investment into GBS diagnostics and treatment innovations.

Treatment delivery methods are evolving, with both parenteral and oral options under exploration. While IVIG remains the gold standard for acute cases, research into oral immunomodulatory treatments is gaining momentum, potentially offering more accessible long-term management solutions for CIDP patients. Pharmacies play a crucial role in GBS treatment distribution. Hospital pharmacies dominate the market due to the need for inpatient care and close monitoring during IVIG or Plasma Exchange therapy. However, retail pharmacies are expanding their role in CIDP management, providing patients with convenient access to maintenance therapies and supportive medications.

With increasing awareness, evolving treatment approaches, and growing pharmaceutical investment, the GBS market is poised for significant growth. Innovations in both acute and chronic care solutions will continue to shape the landscape, creating new opportunities for businesses in healthcare, therapeutics.

Guillain-Barre Syndrome Market Report Highlights:

  • Intravenous Immunoglobulin (IVIG) dominated the Guillain-Barre Syndrome (GBS) treatment market in 2024. This dominance is driven by IVIG's proven efficacy in modulating the immune response, reducing disease progression, and improving recovery rates, making it the preferred first-line treatment for GBS.
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) held the largest market share among GBS subtypes in 2024. As the most common form of GBS, particularly in North America and Europe, AIDP's prevalence significantly influences the demand for effective therapeutic options, further strengthening its market dominance.
  • Parenteral led the GBS treatment market in 2024. Given the critical nature of the disease, IV-administered treatments such as IVIG and plasma exchange ensure rapid and effective therapeutic action, enhancing patient outcomes in both acute and severe cases.
  • Hospital pharmacies remained the dominant distribution channel in 2024. Due to the need for immediate medical intervention and specialized care, hospital pharmacies play a crucial role in ensuring the availability and administration of GBS treatments, particularly in acute care settings.
  • North America led the GBS treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Guillain-Barre Syndrome (GBS) Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing prevalence of Guillain-Barre Syndrome (GBS)
      • 3.3.1.2. Government regulations and guidelines
      • 3.3.1.3. Advancements in treatment options
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Side effects and adverse reactions
      • 3.3.2.2. High cost treatment
  • 3.4. Guillain-Barre Syndrome Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

  • 4.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
  • 4.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Intravenous Immunoglobulin (IVIG)
    • 4.3.1. Intravenous Immunoglobulin (IVIG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Plasma Exchange
    • 4.4.1. Plasma Exchange Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

  • 5.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
  • 5.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
    • 5.3.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    • 5.4.1. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Miller Fisher Syndrome (MFS)
    • 5.5.1. Miller Fisher Syndrome (MFS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Acute Motor Axonal Neuropathy (AMAN)
    • 5.6.1. Acute Motor Axonal Neuropathy (AMAN) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other
    • 5.7.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Guillain- Barre Syndrome (GBS) Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Guillain-Barre Syndrome Market: Route of Administration Segment Dashboard
  • 6.2. Guillain-Barre Syndrome Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Parenteral
    • 6.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Guillain Barre Syndrome (GBS) Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Guillain-Barre Syndrome Market: Distribution Channel Segment Dashboard
  • 7.2. Guillain-Barre Syndrome Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Other Pharmacies
    • 7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Guillain-Barre Syndrome (GBS) Market: Regional Estimates & Trend Analysis

  • 8.1. Guillain-Barre Syndrome Market Share, By Region, 2024 & 2030, USD Million
  • 8.2. North America
    • 8.2.1. North America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Norway
      • 8.3.8.1. Norway Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Sweden Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. China
      • 8.4.2.1. China Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Japan Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Australia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Saudi Arabia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. UAE
      • 8.6.3.1. UAE Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Kuwait
      • 8.6.4.1. Kuwait Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Africa
      • 8.6.5.1. South Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis, 2024
  • 9.5. Company Profiles
    • 9.5.1. AbbVie Inc.
      • 9.5.1.1. Participant's Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Recent Developments/ Strategic Initiatives
    • 9.5.2. Biogen
      • 9.5.2.1. Participant's Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Recent Developments/ Strategic Initiatives
    • 9.5.3. Cadila Pharmaceuticals
      • 9.5.3.1. Participant's Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Recent Developments/ Strategic Initiatives
    • 9.5.4. CSL
      • 9.5.4.1. Participant's Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Recent Developments/ Strategic Initiatives
    • 9.5.5. F. Hoffmann-La Roche Ltd.
      • 9.5.5.1. Participant's Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Recent Developments/ Strategic Initiatives
    • 9.5.6. GSK plc.
      • 9.5.6.1. Participant's Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Recent Developments/ Strategic Initiatives
    • 9.5.7. Grifols S.A.
      • 9.5.7.1. Participant's Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Recent Developments/ Strategic Initiatives
    • 9.5.8. LGM Pharma.
      • 9.5.8.1. Participant's Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Recent Developments/ Strategic Initiatives
    • 9.5.9. Merck & Co., Inc.
      • 9.5.9.1. Participant's Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Recent Developments/ Strategic Initiatives
    • 9.5.10. Octapharma AG
      • 9.5.10.1. Participant's Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Recent Developments/ Strategic Initiatives
    • 9.5.11. Pfizer Inc.
      • 9.5.11.1. Participant's Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Recent Developments/ Strategic Initiatives
    • 9.5.12. Takeda Pharmaceutical Company Limited
      • 9.5.12.1. Participant's Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 5 Global Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 9 North America Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 13 U.S. Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 17 Canada Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Mexico Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 21 Mexico Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Europe Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 25 Europe Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 Europe Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 29 Germany Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Germany Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 U.K. Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 32 U.K. Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 33 U.K. Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 U.K. Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 France Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 France Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 37 France Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 France Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Italy Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 40 Italy Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 41 Italy Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Italy Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Spain Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 Spain Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 45 Spain Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Spain Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Denmark Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 48 Denmark Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 49 Denmark Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Denmark Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Sweden Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Sweden Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 53 Sweden Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Sweden Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Norway Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 56 Norway Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 57 Norway Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 Norway Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 China Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 China Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 65 China Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 China Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Japan Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 68 Japan Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 69 Japan Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Japan Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 India Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 72 India Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 73 India Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 India Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 South Korea Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 76 South Korea Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 77 South Korea Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 South Korea Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Australia Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 80 Australia Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 81 Australia Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Australia Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 Thailand Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 Thailand Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 85 Thailand Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 Thailand Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 Latin America Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 Latin America Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 89 Latin America Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 92 Brazil Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 93 Brazil Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Argentina Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 96 Argentina Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 97 Argentina Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 98 Argentina Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 99 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 100 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 101 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 102 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 103 South Africa Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 104 South Africa Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 105 South Africa Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 111 UAE Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 112 UAE Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 113 UAE Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 114 UAE Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Guillain-Barre syndrome market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook, 2024 (USD billion)
  • Fig. 11 Market trends & outlook
  • Fig. 12 Porter's five force analysis
  • Fig. 13 PESTEL analysis
  • Fig. 14 Guillain-Barre Syndrome market: Therapeutics outlook and key takeaways
  • Fig. 15 Guillain-Barre Syndrome market: Therapeutics movement analysis
  • Fig. 16 Intravenous Immunoglobulin (IVIG) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Plasma Exchange market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Guillain-Barre Syndrome market: Type outlook and key takeaways
  • Fig. 20 Guillain-Barre Syndrome market: Type movement analysis
  • Fig. 21 Acute Inflammatory Demyelinating Polyneuropathy (AIDP) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Miller Fisher Syndrome (MFS) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Acute Motor Axonal Neuropathy (AMAN) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Guillain-Barre Syndrome market: Route of administration outlook and key takeaways
  • Fig. 27 Guillain-Barre Syndrome market: Route of administration movement analysis
  • Fig. 28 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Parenteral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Guillain-Barre Syndrome market: Distribution channel outlook and key takeaways
  • Fig. 31 Guillain-Barre Syndrome market: Distribution channel movement analysis
  • Fig. 32 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Other pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Regional Marketplace: Key Takeaways
  • Fig. 36 Regional Outlook, 2024 & 2030
  • Fig. 37 Global Guillain-Barre syndrome market, Region Movement Analysis
  • Fig. 38 North America Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 40 Canada Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 44 U.K. Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 45 France Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 53 China Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 54 India Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 58 Latin America Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 59 Brazil Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 61 Middle East and Africa Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 64 UAE Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait Guillain-Barre syndrome market, 2018 - 2030 (USD Million)